Briacell is a clinical-stage biotech company that focuses on immuno-oncology and develops personalized immunotherapy for cancer. It provides drug candidates based on whole-cell technology platform and designed to treat breast cancer patients. In addition, the company develops a small molecule program that consists of selective protein kinase C delta inhibitors, which show activity in pre-clinical models of several cancers and fibrotic diseases.